Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A first-in-human phase I study of MORAb-202 in patients with folate receptor alpha-positive advanced solid tumors


03 Mar 2020


Proffered Papers 2: Individual targets


Jun Sato


Annals of Oncology (2020) 31 (suppl_1): S8-S10. 10.1016/annonc/annonc82


J. Sato1, T. Shimizu1, Y. Fujiwara1, K. Yonemori1, T. Koyama1, A. Shimomura1, K. Tamura2, S. Iwasa1, S. Kondo1, K. Sudo1, H. Ikezawa3, M. Nomoto3, R. Nakajima3, T. Miura3, N. Yamamoto1

Author affiliations

  • 1 Department Of Experimental Therapeutics, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Department Of Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Eisai Co. Ltd, 112-8088 - Tokyo/JP


MORAb-202 is a novel antibody-drug conjugate consisting of farletuzumab (a humanized monoclonal antibody that binds to folate receptor alpha (FRA)) paired with a cathepsin B-cleavable linker to eribulin. Here we report preliminary results of part 1 (dose escalation part) from a first-in-human phase 1 study of MORAb-202 in patients (pts) with FRA-positive solid tumors.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings